When it was reported this week that Arcturis Data and Akrivia Health had agreed to combine, the figure that mattered most to most readers was £140m. The figure that will matter more to NHS leaders over the coming year is 100 million: the number of aggregated patient records the merged company will hold, drawn from forty trusts, and offered to the drugs industry as Britain's answer to an American incumbent it has spent two years learning to distrust.

The language used by those briefed on the deal was deliberate. One source described the combined group as the country's largest sovereign healthcare data asset, owned and domiciled in the UK. That word, sovereign, has done a lot of work in NHS technology policy since Palantir won the Federated Data Platform contract in 2023. It has featured in select committee questioning, in trust board papers wary of American cloud dependency, and in the running commentary around Peter Thiel's public remarks about the health service he now helps to run software for. Arcturis, once Sensyne Health and rescued from near collapse in 2022, understands the value of that word better than most: it has spent four years rebuilding a business model around exactly the anxiety a British alternative is designed to soothe.

The timing reinforces the read. NHS England's own data platform has just had its costs revised upward, to as much as £1.1bn according to reporting drawn from National Infrastructure and Service Transformation Authority figures, while the benefits case has shrunk. For reasons unrelated to clinical results, Palantir is concurrently engaged in a different struggle over its work for the Metropolitan Police, which has attracted the attention of the mayor of London and kept the company's name in the news. Against that backdrop, a merger promising scale, domestic ownership and pharmaceutical partnerships with AstraZeneca, GSK, Novartis and Bristol Myers Squibb looks, on the surface, like exactly the kind of resilience the health data debate has been asking for.

It is worth being precise about what sovereignty would actually buy the NHS here, because the term is doing more reassurance than analysis. Ownership and domicile determine who is accountable under UK law and who profits from the arrangement. They do not, by themselves, determine how patient data is governed once it sits inside a commercial platform, how consent operates at scale across forty trusts with different information governance maturity, or how much bargaining leverage any single trust retains once its data has been folded into a network this size. A British company answering to British shareholders can concentrate risk just as effectively as an American one, particularly when the underlying commercial proposition, licensing curated NHS-derived datasets to global pharmaceutical companies, is unchanged by who signs the merger paperwork.

That is the more uncomfortable question sitting underneath the good news framing. NHS trusts already report struggling to hold Palantir to account at the scale of a single national contract. A newly merged Arcturis-Akrivia now represents a comparable point of concentration in the real-world data market, built trust by trust through bilateral partnerships that individually looked unremarkable and collectively now constitute the country's largest such asset. Forty trusts did not collectively negotiate their way into that position. They arrived at it through years of separate agreements that have only become visible as a system now that the sums have been added up publicly.

None of this means the merger should be resisted, or that a British-owned data company is somehow equivalent to the concerns raised about Palantir's ownership and its chairman's stated views on the NHS. It means the reassurance on offer is narrower than the language suggests. If ministers and NHS leaders want the sovereignty argument to carry real weight, it has to extend beyond where a company is headquartered and into how patient data governance, consent architecture and trust-level accountability scale alongside commercial ambition. Otherwise Britain will simply have swapped one concentrated dependency for another, with better public relations attached.